CARE Fertility Birmingham
Birmingham, United Kingdom
NCT Number: NCT04170517
Frozen embryo transfer (FET) cycles have become more common in recent years due to a push towards elective single embryo transfer (SET). While it is known that progesterone supplementation during the luteal phase improves clinical pregnancy rates, there is a paucity of prospective data on the impact of serum progesterone levels on pregnancy outcomes in FET cycles. This multicentre prospective cohort study aims to investigate the association between serum progesterone levels on the day of FET and pregnancy outcomes, and to determine a serum progesterone cut-off value above which clinical pregnancy and live birth are more likely to occur. Women undergoing ART-FET cycles at CARE Fertility clinics in the UK will be recruited and their serum progesterone measured on the day of frozen embryo transfer. Follow-up data will be stored in electronic patient records and analysed to determine whether a low serum progesterone level on the day of FET adversely affects ART outcomes.
Looking for future studies?
Notify MeFemale
Observational
Birmingham, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Measurement of serum progesterone on the day of FET
Time frame: 18 months
Birth of a live fetus at 24 or more weeks of gestational age
Time frame: 18 months
Any clinical pregnancy lost before week 12 of gestation per participant (number of events/number of participants, %)
Time frame: 18 months
Number of gestational sacs seen in a 2D transvaginal ultrasound scan divided by the number of embryos transferred per patient (number of events/number of embryos transferred, %)
Time frame: 18 months
Positive pregnancy test following embryo transfer per participant (number of events/number of participants, %)
Time frame: 18 months
Presence of at least one gestational sac on ultrasound (number of events/number of participants, %)
Time frame: 18 months
number of events/number of participants, %
CARE Fertility UK
Other
Acronym: ProFET
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04417569
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Abu Dhabi, United Arab Emirates
View Trial DetailsNCT06419127
Aneuploidy, Chromosome Aberrations
Fort Lauderdale, Florida, United States
View Trial DetailsNCT03712982
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Waltham, Massachusetts, United States
View Trial DetailsNCT07288866
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Clermont-Ferrand, Auvergne, France
View Trial Details